Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ERIC 2018 | How biomarkers can aid clinical decision making in CLL

Kostas Stamatopoulos • 25 Oct 2018
ERIC 2018
Chronic Lymphocytic Leukemia Leukemia

Kostas Stamatopoulos, MD, PhD, of the Center for Research and Technology Hellas, Thessaloniki, Greece, discusses precision medicine and how biomarkers can aid in clinical decision making in chronic lymphocytic leukemia (CLL). This video was recorded at the European Research Initiative on CLL (ERIC) International Meeting 2018, held in Barcelona, Spain.

More from Kostas Stamatopoulos

3:19
Translating scientific advances into clinical success in CLL: satellite symposium highlights
Kostas Stamatopoulos • 19 Mar 2022
2:02
The link between the tumor microenvironment & gene expression in CLL
Kostas Stamatopoulos • 19 Mar 2022
1:46
Pathogenesis and transformation in CLL: session highlights
Kostas Stamatopoulos • 19 Mar 2022
2:54
The definition of high-risk CLL
Kostas Stamatopoulos • 19 Mar 2022

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals